Tumor-Infiltrating Lymphocyte therapy is a form of adoptive cell therapy used in cancer treatment that harnesses the patient鈥檚 own immune cells to fight tumors. TILs are a type of immune cell that naturally penetrate tumor tissues. In TIL therapy, these lymphocytes are extracted from the patient's tumor, expanded in large numbers in a laboratory, and then reintroduced into the patient after the tumor has been reduced or suppressed, typically following lymphodepleting chemotherapy.TIL therapy has shown promise particularly in the treatment of melanoma and other solid tumors.
The global Tumor-Infiltrating Lymphocyte Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Tumor-Infiltrating Lymphocyte Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Tumor-Infiltrating Lymphocyte Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Tumor-Infiltrating Lymphocyte Therapy in Melanoma is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Tumor-Infiltrating Lymphocyte Therapy include Iovance Biotherapeutics, Moffitt Cancer Center, Essen Biotech, Turnstone Biologics, Obsidian Therapeutics, Hervor Therapeutics, Intima Bioscience, Instil Bio, Shanghai Juncell Therapeutics, Suzhou BlueHorse Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Tumor-Infiltrating Lymphocyte Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor-Infiltrating Lymphocyte Therapy.
The Tumor-Infiltrating Lymphocyte Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tumor-Infiltrating Lymphocyte Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumor-Infiltrating Lymphocyte Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Iovance Biotherapeutics
Moffitt Cancer Center
Essen Biotech
Turnstone Biologics
Obsidian Therapeutics
Hervor Therapeutics
Intima Bioscience
Instil Bio
Shanghai Juncell Therapeutics
Suzhou BlueHorse Therapeutics
Grit Biotechnology
TCRCure Biopharma
BioSyngen
Sino-Cell Biomed
Segment by Type
Combined with IL-2
Not Combined with IL-2
Segment by Application
Melanoma
Cervical Cancer
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tumor-Infiltrating Lymphocyte Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Combined with IL-2
1.2.3 Not Combined with IL-2
1.3 麻豆原创 by Application
1.3.1 Global Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Melanoma
1.3.3 Cervical Cancer
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Perspective (2019-2030)
2.2 Global Tumor-Infiltrating Lymphocyte Therapy Growth Trends by Region
2.2.1 Global Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Tumor-Infiltrating Lymphocyte Therapy Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Tumor-Infiltrating Lymphocyte Therapy Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Dynamics
2.3.1 Tumor-Infiltrating Lymphocyte Therapy Industry Trends
2.3.2 Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Drivers
2.3.3 Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Challenges
2.3.4 Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor-Infiltrating Lymphocyte Therapy Players by Revenue
3.1.1 Global Top Tumor-Infiltrating Lymphocyte Therapy Players by Revenue (2019-2024)
3.1.2 Global Tumor-Infiltrating Lymphocyte Therapy Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Tumor-Infiltrating Lymphocyte Therapy Revenue
3.4 Global Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Concentration Ratio
3.4.1 Global Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor-Infiltrating Lymphocyte Therapy Revenue in 2023
3.5 Global Key Players of Tumor-Infiltrating Lymphocyte Therapy Head office and Area Served
3.6 Global Key Players of Tumor-Infiltrating Lymphocyte Therapy, Product and Application
3.7 Global Key Players of Tumor-Infiltrating Lymphocyte Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor-Infiltrating Lymphocyte Therapy Breakdown Data by Type
4.1 Global Tumor-Infiltrating Lymphocyte Therapy Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Tumor-Infiltrating Lymphocyte Therapy Forecasted 麻豆原创 Size by Type (2025-2030)
5 Tumor-Infiltrating Lymphocyte Therapy Breakdown Data by Application
5.1 Global Tumor-Infiltrating Lymphocyte Therapy Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Tumor-Infiltrating Lymphocyte Therapy Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size (2019-2030)
6.2 North America Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size by Country (2019-2024)
6.4 North America Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size (2019-2030)
7.2 Europe Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size by Country (2019-2024)
7.4 Europe Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size (2019-2030)
9.2 Latin America Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Tumor-Infiltrating Lymphocyte Therapy 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Iovance Biotherapeutics
11.1.1 Iovance Biotherapeutics Company Details
11.1.2 Iovance Biotherapeutics Business Overview
11.1.3 Iovance Biotherapeutics Tumor-Infiltrating Lymphocyte Therapy Introduction
11.1.4 Iovance Biotherapeutics Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.1.5 Iovance Biotherapeutics Recent Development
11.2 Moffitt Cancer Center
11.2.1 Moffitt Cancer Center Company Details
11.2.2 Moffitt Cancer Center Business Overview
11.2.3 Moffitt Cancer Center Tumor-Infiltrating Lymphocyte Therapy Introduction
11.2.4 Moffitt Cancer Center Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.2.5 Moffitt Cancer Center Recent Development
11.3 Essen Biotech
11.3.1 Essen Biotech Company Details
11.3.2 Essen Biotech Business Overview
11.3.3 Essen Biotech Tumor-Infiltrating Lymphocyte Therapy Introduction
11.3.4 Essen Biotech Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.3.5 Essen Biotech Recent Development
11.4 Turnstone Biologics
11.4.1 Turnstone Biologics Company Details
11.4.2 Turnstone Biologics Business Overview
11.4.3 Turnstone Biologics Tumor-Infiltrating Lymphocyte Therapy Introduction
11.4.4 Turnstone Biologics Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.4.5 Turnstone Biologics Recent Development
11.5 Obsidian Therapeutics
11.5.1 Obsidian Therapeutics Company Details
11.5.2 Obsidian Therapeutics Business Overview
11.5.3 Obsidian Therapeutics Tumor-Infiltrating Lymphocyte Therapy Introduction
11.5.4 Obsidian Therapeutics Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.5.5 Obsidian Therapeutics Recent Development
11.6 Hervor Therapeutics
11.6.1 Hervor Therapeutics Company Details
11.6.2 Hervor Therapeutics Business Overview
11.6.3 Hervor Therapeutics Tumor-Infiltrating Lymphocyte Therapy Introduction
11.6.4 Hervor Therapeutics Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.6.5 Hervor Therapeutics Recent Development
11.7 Intima Bioscience
11.7.1 Intima Bioscience Company Details
11.7.2 Intima Bioscience Business Overview
11.7.3 Intima Bioscience Tumor-Infiltrating Lymphocyte Therapy Introduction
11.7.4 Intima Bioscience Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.7.5 Intima Bioscience Recent Development
11.8 Instil Bio
11.8.1 Instil Bio Company Details
11.8.2 Instil Bio Business Overview
11.8.3 Instil Bio Tumor-Infiltrating Lymphocyte Therapy Introduction
11.8.4 Instil Bio Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.8.5 Instil Bio Recent Development
11.9 Shanghai Juncell Therapeutics
11.9.1 Shanghai Juncell Therapeutics Company Details
11.9.2 Shanghai Juncell Therapeutics Business Overview
11.9.3 Shanghai Juncell Therapeutics Tumor-Infiltrating Lymphocyte Therapy Introduction
11.9.4 Shanghai Juncell Therapeutics Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.9.5 Shanghai Juncell Therapeutics Recent Development
11.10 Suzhou BlueHorse Therapeutics
11.10.1 Suzhou BlueHorse Therapeutics Company Details
11.10.2 Suzhou BlueHorse Therapeutics Business Overview
11.10.3 Suzhou BlueHorse Therapeutics Tumor-Infiltrating Lymphocyte Therapy Introduction
11.10.4 Suzhou BlueHorse Therapeutics Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.10.5 Suzhou BlueHorse Therapeutics Recent Development
11.11 Grit Biotechnology
11.11.1 Grit Biotechnology Company Details
11.11.2 Grit Biotechnology Business Overview
11.11.3 Grit Biotechnology Tumor-Infiltrating Lymphocyte Therapy Introduction
11.11.4 Grit Biotechnology Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.11.5 Grit Biotechnology Recent Development
11.12 TCRCure Biopharma
11.12.1 TCRCure Biopharma Company Details
11.12.2 TCRCure Biopharma Business Overview
11.12.3 TCRCure Biopharma Tumor-Infiltrating Lymphocyte Therapy Introduction
11.12.4 TCRCure Biopharma Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.12.5 TCRCure Biopharma Recent Development
11.13 BioSyngen
11.13.1 BioSyngen Company Details
11.13.2 BioSyngen Business Overview
11.13.3 BioSyngen Tumor-Infiltrating Lymphocyte Therapy Introduction
11.13.4 BioSyngen Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.13.5 BioSyngen Recent Development
11.14 Sino-Cell Biomed
11.14.1 Sino-Cell Biomed Company Details
11.14.2 Sino-Cell Biomed Business Overview
11.14.3 Sino-Cell Biomed Tumor-Infiltrating Lymphocyte Therapy Introduction
11.14.4 Sino-Cell Biomed Revenue in Tumor-Infiltrating Lymphocyte Therapy Business (2019-2024)
11.14.5 Sino-Cell Biomed Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Iovance Biotherapeutics
Moffitt Cancer Center
Essen Biotech
Turnstone Biologics
Obsidian Therapeutics
Hervor Therapeutics
Intima Bioscience
Instil Bio
Shanghai Juncell Therapeutics
Suzhou BlueHorse Therapeutics
Grit Biotechnology
TCRCure Biopharma
BioSyngen
Sino-Cell Biomed
听
听
*If Applicable.
